Review Article

Treatment of Neuroendocrine Tumor Liver Metastases

Table 3

Summary of outcomes for intra-arterial therapy of neuroendocrine liver metastases.

First author, publication yearNumber of embolized patientsSurvival dataComments

Paprottka, 2011 [29]42
(90Y radioembolization)
40 of 42 patients alive with mean followup of 16.2 monthsNo radiation-induced liver failure; 36 of 38 symptomatic patients improved clinically within 3 months

Kennedy, 2008 [30]148
(90Y radioembolization)
Median OS: 70 monthsNo radiation-induced liver failure

Strosberg, 2006 [31]84
(HAE)
Median OS: 36 monthsFewer symptoms in 44 of 55 symptomatic patients

Gupta, 2005 [32]123
(74 HAE, 49 HACE)
Median OS (carcinoid): 33.8 months
Median OS (islet cell): 23.2 months
Male gender (versus female) predicted worse OS ( ) for carcinoid,
bone mets predicted worse OS for islet cell ( )

Dong, 2011 [33]123
(HACE)
Mean OS: 39.6 months
5-year OS: 36%
10-year OS: 20%
Baseline albumin <3.5 g/dL was multivariate predictor for poorer OS ( )